HUE067417T2 - Készítmények és módszerek EGFR-pozitív rákok kezelésére - Google Patents

Készítmények és módszerek EGFR-pozitív rákok kezelésére

Info

Publication number
HUE067417T2
HUE067417T2 HUE21769291A HUE21769291A HUE067417T2 HU E067417 T2 HUE067417 T2 HU E067417T2 HU E21769291 A HUE21769291 A HU E21769291A HU E21769291 A HUE21769291 A HU E21769291A HU E067417 T2 HUE067417 T2 HU E067417T2
Authority
HU
Hungary
Prior art keywords
compositions
methods
positive cancers
egfr positive
treating egfr
Prior art date
Application number
HUE21769291A
Other languages
English (en)
Hungarian (hu)
Inventor
Julyun Oh
Han Xu
Carl Alexander Kamb
Original Assignee
A2 Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A2 Biotherapeutics Inc filed Critical A2 Biotherapeutics Inc
Publication of HUE067417T2 publication Critical patent/HUE067417T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HUE21769291A 2020-08-20 2021-08-19 Készítmények és módszerek EGFR-pozitív rákok kezelésére HUE067417T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063068249P 2020-08-20 2020-08-20
US202063105639P 2020-10-26 2020-10-26
US202163230632P 2021-08-06 2021-08-06

Publications (1)

Publication Number Publication Date
HUE067417T2 true HUE067417T2 (hu) 2024-10-28

Family

ID=77711489

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE21769291A HUE067417T2 (hu) 2020-08-20 2021-08-19 Készítmények és módszerek EGFR-pozitív rákok kezelésére

Country Status (20)

Country Link
US (2) US11602544B2 (cg-RX-API-DMAC10.html)
EP (2) EP4058474B1 (cg-RX-API-DMAC10.html)
JP (2) JP7621461B2 (cg-RX-API-DMAC10.html)
KR (1) KR102960041B1 (cg-RX-API-DMAC10.html)
AU (1) AU2021328478A1 (cg-RX-API-DMAC10.html)
CA (1) CA3189510A1 (cg-RX-API-DMAC10.html)
DK (1) DK4058474T3 (cg-RX-API-DMAC10.html)
ES (1) ES2984902T3 (cg-RX-API-DMAC10.html)
FI (1) FI4058474T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20240903T1 (cg-RX-API-DMAC10.html)
HU (1) HUE067417T2 (cg-RX-API-DMAC10.html)
IL (1) IL300629A (cg-RX-API-DMAC10.html)
LT (1) LT4058474T (cg-RX-API-DMAC10.html)
MX (1) MX2023002104A (cg-RX-API-DMAC10.html)
PL (1) PL4058474T3 (cg-RX-API-DMAC10.html)
PT (1) PT4058474T (cg-RX-API-DMAC10.html)
RS (1) RS65802B1 (cg-RX-API-DMAC10.html)
SI (1) SI4058474T1 (cg-RX-API-DMAC10.html)
TW (1) TWI915404B (cg-RX-API-DMAC10.html)
WO (1) WO2022040444A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4058474B1 (en) 2020-08-20 2024-05-08 A2 Biotherapeutics, Inc. Compositions and methods for treating egfr positive cancers
US20240180969A1 (en) * 2021-04-01 2024-06-06 A2 Biotherapeutics, Inc. Polypeptides targeting hla-a*11 and methods of use thereof
JP2026527004A (ja) * 2023-08-02 2026-08-10 エー2 バイオセラピューティクス, インコーポレイテッド Hla-a*03の発現の喪失を伴うがんを治療するための組成物および方法
KR20260114545A (ko) * 2023-10-20 2026-07-22 에이투 바이오쎄라퓨틱스, 인크. 조작된 인터루킨 및 이의 용도
CN122535421A (zh) * 2023-10-20 2026-08-07 A2生物治疗股份有限公司 用于治疗血癌的组合物和方法
WO2026019829A1 (en) * 2024-07-15 2026-01-22 A2 Biotherapeutics, Inc. Compositions and methods for stimulating t cells used in cell therapy with a bispecific bridging molecule

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
CA2559955C (en) 2004-03-15 2016-02-16 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded rna
ES2387809T3 (es) * 2004-03-19 2012-10-02 Imclone Llc Anticuerpo frente al receptor del factor de crecimiento epidérmico humano
AU2005250408B2 (en) 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
CA3285826A1 (en) 2012-02-22 2026-03-02 The Trustees Of The University Of Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
US20150183877A1 (en) * 2012-07-18 2015-07-02 Eli Lilly And Company Multi-Specific IgG-(Fab)2 Constructs Containing T-Cell Receptor Constant Domains
CN105209621B (zh) 2012-12-12 2021-05-25 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
KR102955556B1 (ko) 2012-12-12 2026-04-22 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물
AU2014386824B2 (en) 2013-03-15 2019-05-09 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
ES2769574T3 (es) 2013-03-15 2020-06-26 Michael C Milone Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
EP3027204B1 (en) 2013-07-29 2022-01-05 2seventy bio, Inc. Multipartite signaling proteins and uses thereof
EP3858379A1 (en) 2013-11-21 2021-08-04 Autolus Limited Cell
KR20240164967A (ko) 2014-02-04 2024-11-21 카이트 파마 인코포레이티드 B 세포 악성종양 및 다른 암을 치료하는데 유용한 자가 t 세포 및 그의 조성물의 생산 방법
RU2752933C2 (ru) * 2014-03-11 2021-08-11 Селлектис Способ создания т-клеток, пригодных для аллогенной трансплантации
CA2967222C (en) 2014-11-12 2023-10-31 Rinat Neuroscience Corp. Inhibitory chimeric antigen receptors
US20170296623A1 (en) 2014-12-17 2017-10-19 Cellectis INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
EP3262166A4 (en) 2015-02-24 2018-08-15 The Regents of The University of California Binding-triggered transcriptional switches and methods of use thereof
WO2016142532A1 (en) 2015-03-11 2016-09-15 Cellectis Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients
US20190119385A1 (en) 2015-03-27 2019-04-25 University Of Southern California Hla-g as a novel target for car t-cell immunotherapy
GB201509413D0 (en) 2015-06-01 2015-07-15 Ucl Business Plc Fusion protein
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
MX2018005618A (es) 2015-11-05 2018-08-01 Juno Therapeutics Inc Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados.
EP3377523A4 (en) 2015-11-19 2019-06-19 The Regents of The University of California CONDITIONALLY REPRIMATABLE IMMUNOCELL RECEPTORS AND METHOD FOR USE THEREOF
EP3380602A4 (en) 2015-11-23 2019-09-25 Trustees of Boston University METHOD AND COMPOSITIONS RELATED TO CHIMERIC ANTIGEN RECEPTORS
WO2017091905A1 (en) 2015-12-02 2017-06-08 Innovative Targeting Solutions Inc. Single variable domain t-cell receptors
US20190241910A1 (en) 2016-03-11 2019-08-08 Bluebird Bio, Inc. Genome edited immune effector cells
CA3029121A1 (en) 2016-06-29 2018-01-04 Crispr Therapeutics Ag Compositions and methods for gene editing
EP3263595A1 (en) 2016-06-30 2018-01-03 Medizinische Hochschule Hannover Fusion protein for use in the treatment of hvg disease
MX2019003462A (es) 2016-09-28 2019-08-16 Gavish Galilee Bio Appl Ltd Una plataforma universal para el tratamiento con car que se dirige a una novedosa firma antigenica del cancer.
US20190375815A1 (en) 2017-01-31 2019-12-12 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
WO2018148454A1 (en) 2017-02-09 2018-08-16 The Regents Of The University Of California Chimeric t cell antigen receptors and methods of use thereof
GB201707783D0 (en) 2017-05-15 2017-06-28 Autolus Ltd Cell
WO2018211244A1 (en) 2017-05-15 2018-11-22 Autolus Limited A cell comprising a chimeric antigen receptor (car)
GB201707779D0 (en) 2017-05-15 2017-06-28 Autolus Ltd Cell
KR102742220B1 (ko) 2017-09-19 2024-12-17 더 유니버시티 오브 브리티쉬 콜롬비아 항-hla-a2 항체 및 그 사용 방법
PL3688155T3 (pl) 2017-09-28 2023-09-11 Immpact-Bio Ltd. Uniwersalna platforma do wytwarzania hamującego chimerycznego receptora antygenowego (icar)
EP3707166A4 (en) 2017-11-06 2021-11-24 Daniel J. Monticello CHEMICAL ANTIGENIC RECEPTOR SYSTEMS WITH NEGATIVE DOMINANT LIGAND
WO2019241549A1 (en) 2018-06-15 2019-12-19 A2 Biotherapeutics, Inc. Foxp3-expressing car-t regulatory cells
BR112021006100A2 (pt) * 2018-09-28 2021-07-20 Immpact-Bio Ltd. métodos para identificação de pares de receptor de antígeno ativador (acar)/receptor de antígeno quimérico inibitório (icar) para uso em terapias de câncer
JP2022512594A (ja) 2018-10-05 2022-02-07 ザンクト アンナ キンダークレプスフォルシュング キメラ抗原受容体(car)の群
EP3632461A1 (en) 2018-10-05 2020-04-08 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
WO2020264200A1 (en) * 2019-06-26 2020-12-30 Amunix Pharmceuticals, Inc. Cd3 antigen binding fragments and compositions comprising same
EP4010377A4 (en) * 2019-08-09 2023-09-06 A2 Biotherapeutics, Inc. CELL SURFACE RECEPTORS THAT RESPOND TO LOSS OF HETEROZYGOSIS
WO2021030182A1 (en) 2019-08-09 2021-02-18 A2 Biotherapeutics, Inc. Bifunctional single variable domain t cell receptors and uses thereof
WO2021030153A2 (en) 2019-08-09 2021-02-18 A2 Biotherapeutics, Inc. Engineered t cell receptors and uses thereof
EP4017510A4 (en) 2019-08-20 2023-11-22 Senti Biosciences, Inc. CHIMERIC INHIBITOR RECEPTOR
US20220389075A1 (en) 2019-11-12 2022-12-08 A2 Biotherapeutics, Inc. Engineered t cell receptors and uses thereof
WO2021119489A1 (en) 2019-12-11 2021-06-17 A2 Biotherapeutics, Inc. Lilrb1-based chimeric antigen receptor
WO2021222576A1 (en) 2020-05-01 2021-11-04 A2 Biotherapeutics, Inc. Pag1 fusion proteins and methods of making and using same
EP4058474B1 (en) 2020-08-20 2024-05-08 A2 Biotherapeutics, Inc. Compositions and methods for treating egfr positive cancers

Also Published As

Publication number Publication date
EP4058474A1 (en) 2022-09-21
ES2984902T3 (es) 2024-10-31
PL4058474T3 (pl) 2024-09-23
KR102960041B1 (ko) 2026-05-04
TW202214846A (zh) 2022-04-16
BR112023002668A2 (pt) 2023-05-02
US11602544B2 (en) 2023-03-14
JP7621461B2 (ja) 2025-01-24
JP2024159820A (ja) 2024-11-08
JP2023538116A (ja) 2023-09-06
US20220273721A1 (en) 2022-09-01
CA3189510A1 (en) 2022-02-24
DK4058474T3 (da) 2024-07-22
EP4058474B1 (en) 2024-05-08
KR20230052289A (ko) 2023-04-19
FI4058474T3 (fi) 2024-07-01
US20230277593A1 (en) 2023-09-07
WO2022040444A1 (en) 2022-02-24
HRP20240903T1 (hr) 2024-10-11
SI4058474T1 (sl) 2024-09-30
EP4442815A3 (en) 2025-01-01
RS65802B1 (sr) 2024-08-30
EP4442815A2 (en) 2024-10-09
IL300629A (en) 2023-04-01
LT4058474T (lt) 2024-08-26
TWI915404B (zh) 2026-02-21
PT4058474T (pt) 2024-07-09
AU2021328478A1 (en) 2023-04-20
MX2023002104A (es) 2023-07-10

Similar Documents

Publication Publication Date Title
IL286350A (en) Preparations and methods for the treatment of cancer
ZA202006627B (en) Methods and compositions for treating cancer
IL288914A (en) Preparations and methods for the treatment of cancer
ZA202104870B (en) Methods and compositions for treating cancer
IL300067A (en) Preparations and methods for the treatment of cancers
IL309296A (en) Methods and compositions for the treatment of angiotensinogen-related disorder (AGT-)
EP4025590A4 (en) METHODS AND COMPOSITIONS FOR TREATING CANCER
SG11202012435UA (en) Compositions and methods for treating cancer
IL287982A (en) Preparations and methods for the treatment of cancer
IL315800A (en) Preparations and methods for the treatment of cancer
EP3930705A4 (en) METHODS AND COMPOSITIONS FOR TREATING CANCER
PT4058474T (pt) Composições e métodos para tratamento de cancros positivos para egfr
GB2642787B (en) Probiotic compositions for treating and preventing colorectal cancer
EP4077690A4 (en) METHODS AND COMPOSITIONS FOR TREATING CANCER
IL286153A (en) Methods and preparations for the treatment of cancer
IL282948B2 (en) Cancer treatment preparations and methods
IL309120A (en) Methods and compositions for the treatment of cancer
IL309071A (en) Methods and compositions for the treatment of cancer
EP3959199A4 (en) Compositions and methods for treating ras-mutant cancers
IL308530A (en) Preparations and methods for treating lung cancer
SG11202101712XA (en) Kits and methods for treating cancers
EP4031253A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYC-ASSOCIATED CANCERS
EP4149508A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF CANCER
IL299039A (en) Methods and preparations for the treatment of triple-negative breast cancer
IL312846A (en) Methods and preparations for the treatment of cancer